Patients who have achieved very low low-density lipoprotein CH (LDL-C) levels in clinical trials
have shown the lowest cardio-vascular risk. The current clinical guidelines set such a concentration for LDL-C
as < 1.4 mmol/L. However, the question of minimum permissible target values of the lipids remains unresolved.
A number of experimental and clinical studies showed some unfavorable consequences of low LDL-C
levels At the same time, the modern arsenal of lipid lowering drugs allows reducing LDL-C levels to extremely
low values. This review presents an analysis of literature about the safety of low lipid spectrum parameters.
Keywords: Low-density lipoprotein CH (LDL-C), PCSK9 inhibitors, statins, diabetes mellitus, immune system, malignant neoplasms, brain
Rights & PermissionsPrintExport